TARGAZYME, INC.

Biotech · Private

Engineered regulatory T cells treated with TZ101 enzyme and substrate to enhance homing and engraftment for preventing graft-versus-host disease in stem cell transplants

targazyme.com →
Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
17
1 granted · 16 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD$1,526,626
Federal grantDepartment of Health and Human Services · Phase II · A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD$467,137
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3217MULTITARGA LLC——
3218Shield Pharma LLC——
3219QWIXEL THERAPEUTICS, LLC——
3220TARGAZYME, INC.——
3221Rondo Therapeutics——
3222GROW BIOMEDICINE LLC——
3223VELUM INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 17
  • Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication
  • Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha, 1,3 Fucosyltransferaseapplication
  • Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha 1,3 Fucosyltransferaseapplication
  • Augmentation of Cell Therapy Efficacy Including Treatment with Alpha 1,3 Fucosyltransferasegranted
  • Manufacture And Cryopreservation Of Fucosylated Cells For Therapeutic Useapplication
  • Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Useapplication
  • Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Useapplication
  • Augmentation of Cell Therapy Efficacy Including Treatment With Alpha 1,3 Fucosyltransferaseapplication
  • Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha 1-3 Fucoslytransferaseapplication
  • Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication
  • Compositions And Systems For Combinatorial Therapies Containing Fucosylated Stem Cells And Hematopoietic Enhancers And/or Immunotherapeutics And Methods Of Production And Use Thereofapplication
  • Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.